Table 3.
Univariate and multivariate Cox regression for overall survival
| Univariate | Multivariate | |||
|---|---|---|---|---|
| Hazard ratio | P‐value | Hazard ratio | P‐value | |
| Fractionation scheme | ||||
| Long‐Course RT | Reference Group | Reference Group | ||
| Short‐Course RT | 1.64 (1.40‐1.92) | <.0001 | 1.57 (1.34‐1.85) | <.0001 |
| Hormone therapy | ||||
| Yes | Reference Group | Reference Group | ||
| No | 1.42 (1.19‐1.71) | <.0001 | 1.36 (1.13‐1.63) | .001 |
| Chemotherapy | ||||
| Yes | Reference Group | — | ||
| No | 0.94 (0.75‐1.18) | .617 | ||
| Clinical T‐Stage | ||||
| T1 | Reference Group | Reference Group | ||
| T2 | 1.04 (0.86‐1.25) | .676 | 1.00 (0.83‐1.20) | .970 |
| T3 | 0.83 (0.51‐1.36) | .436 | 0.94 (0.73‐1.20) | .598 |
| T4 | 1.32 (1.05‐1.66) | .018 | 1.26 (1.00‐1.58) | .054 |
| TX | 1.11 (0.78‐1.59) | .556 | 1.01 (0.70‐1.46) | .949 |
| Unknown | 1.24 (1.06‐1.45) | .008 | 1.17 (0.99‐1.37) | .061 |
| Age | ||||
| <75 y | Reference Group | Reference Group | ||
| ≥75 y | 1.52 (1.41‐1.78) | <.0001 | 1.70 (1.32‐2.20) | <.0001 |
| Race | ||||
| White | Reference Group | — | ||
| Black | 0.92 (0.79‐1.07) | .292 | ||
| Other | 0.78 (0.58‐1.05) | .099 | ||
| Year of diagnosis | ||||
| 2010 | Reference Group | — | ||
| 2011 | 0.90 (0.76‐1.05) | .177 | ||
| 2012 | 1.0 (0.85‐1.17) | .969 | ||
| 2013 | 0.93 (0.78‐1.10) | .400 | ||
| Charlson‐Deyo Comorbidity | ||||
| 0 | Reference Group | Reference Group | ||
| 1 | 1.19 (1.02‐1.39) | .030 | 1.19 (1.02‐1.38) | .029 |
| >1 | 1.59 (1.29‐1.95) | <.0001 | 1.44 (1.17‐1.78) | .001 |
| Site of treatment | ||||
| Extremity | Reference Group | — | ||
| Spine | 1.10 (0.88‐1.38) | .388 | ||
| Ribs | 1.43 (0.83‐2.47) | .204 | ||
| Hip | 0.88 (0.67‐1.15) | .340 | ||
| Pelvic bones | 0.92 (0.70‐1.22) | .577 | ||
| Shoulder | 1.29 (0.87‐1.92) | .210 | ||
| Facility type | ||||
| Integrated Network Cancer Program | Reference Group | — | ||
| Academic/Research Program | 0.86 (0.70‐1.04) | .124 | ||
| Community Caner Program | 1.10 (0.87‐1.41) | .423 | ||
| Comprehensive Community Cancer Program | 0.86 (0.70‐1.04) | .498 | ||
| Insurance status | ||||
| Not insured | Reference Group | Reference Group | ||
| Medicaid | 1.06 (0.78‐1.43) | .705 | 1.04 (0.77‐1.41) | .795 |
| Medicare | 1.32 (1.05‐1.67) | .018 | 1.09 (0.85‐1.34) | .499 |
| Other government | 1.06 (0.63‐1.78) | .836 | 1.02 (0.60‐1.72) | .946 |
| Private | 0.87 (0.68‐1.12) | .281 | 0.86 (0.67‐1.11) | .246 |
| Unknown | 0.98 (0.60‐1.62) | .939 | 0.88 (0.53‐1.46) | .167 |
| Income | ||||
| <$38 000 | Reference Group | — | ||
| $38 000‐47 999 | 0.97 (0.82‐1.15) | .722 | ||
| $48 000‐62 999 | 0.94 (0.79‐1.11) | .445 | ||
| >$63 000 | 0.92 (0.78‐1.08) | .303 | ||
| Unknown | 1.92 (0.99‐3.75) | .054 | ||
| Distance | ||||
| 0‐5 miles | Reference Group | Reference Group | ||
| >5‐10 miles | 0.87 (0.75‐1.01) | .074 | 0.85 (0.73‐0.99) | .042 |
| >10‐15 miles | 0.75 (0.62‐0.91) | .003 | 0.73 (0.60‐0.90) | .002 |
| >15 miles | 0.92 (0.80‐1.06) | .251 | 0.92 (0.79‐1.06) | .230 |
Bold value represent statistical significance of the hazards ratio between short‐course and long‐course radiation therapy (P < 0.05).